FibroGen said it plans on implementing immediate and significant cost reduction plan in the U.S…Terminate pamrevlumab research and development R&D investment and expeditiously wind down remaining obligations The company noted it will reduce U.S. workforce by approximately 75%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
- FibroGen to Report Second Quarter 2024 Financial Results
- Biotech Alert: Searches spiking for these stocks today
- Truist biotech analyst holds an analyst/industry conference call
- Largest borrow rate increases among liquid names